Skip to main content
Premium Trial:

Request an Annual Quote

Compugen Q2 Revenues Flat, Losses Narrow Slightly

NEW YORK, July 23 - Compugen today reported nearly flat revenues for the second quarter, amid slightly narrowed net losses.

 

The Tel Aviv, Israel company had second-quarter revenues of $2.9 million, compared to $2.8  million for the second quarter of 2002.

 

Compugen's R&D expenses were up slightly, to $3.4 million, from $3.0 million for the year-ago quarter.

 

The company's net losses came to $2.4 million, compared to $2.8 million for the second quarter of 2002.

 

As of June 30, the company had $34.8 million in cash, cash equivalents, short-term cash deposits, and marketable securities.

 

Compugen was to hold a conference call to discuss these results at 10AM today. For more information go to http://www.cgen.com.

The Scan

Renewed Gain-of-Function Worries

The New York Times writes that the pandemic is renewing concerns about gain-of-function research.

Who's Getting the Patents?

A trio of researchers has analyzed gender trends in biomedical patents issued between 1976 and 2010 in the US, New Scientist reports.

Other Uses

CBS Sunday Morning looks at how mRNA vaccine technology could be applied beyond SARS-CoV-2.

PLOS Papers Present Analysis of Cervicovaginal Microbiome, Glycosylation in Model Archaea, More

In PLOS this week: functional potential of the cervicovaginal microbiome, glycosylation patterns in model archaea, and more.